Skip to main content

Unable to load price data. Sorry.


Celgene Corp (NASDAQ:CELG.DL)

CAPS Rating: No stars

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:CELG.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFPencils (99.93)
Submitted May 21, 2018

Taking a bit of a flyer on this one given the leadership shuffling going on and questions surrounding some drugs in its pipeline. But despite the near-term challenges, Celgene is still producing more than $3.7 billion in FCF annually and is now… More

NetscribeBiotech (86.71)
Submitted February 22, 2007

Celgene is a biopharmaceutical company focused on novel therapies to treat a broad range of hematopoietic, immunological, neuronal, and cancerous conditions. Celgene currently markets Thalomid for ENL and multiple myeloma, Revlimid for… More



  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about CELG.DL.

No one has written a Pitch for CELG.DL stock yet. Tell us why you think CELG.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in CELG.DL.

No players have picked CELG.DL yet. Tell us why you think CELG.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CELG.DL.